Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02633007 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma
A Phase 1 study of Asthma, sponsored by Acorda Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 3
- Study locations
NCT02633007 is a Phase 1 study of Asthma that has completed, run by Acorda Therapeutics. The registered enrollment target is 25 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT02633007, a Phase 1 study of Asthma, has completed, sponsored by Acorda Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is a double-blind, randomized, placebo-controlled, 2-period, crossover study to evaluate safety and PK of 3 doses of CVT 301 levodopa (l-dopa) in adults with asthma.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Carbidopa
- DRUG CVT-301 (levodopa inhalation powder)
Study Locations (3)
Florida
- Site 002 - Daytona Beach
Massachusetts
- Site 001 - North Dartmouth
Texas
- Site 003 - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02633007
The ClinicalTrials.gov registry entry for NCT02633007 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (98% lower). The listed sponsor is Acorda Therapeutics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02633007 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT02633007 about?
NCT02633007 is a clinical study titled "A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma". This study is a double-blind, randomized, placebo-controlled, 2-period, crossover study to evaluate safety and PK of 3 doses of CVT 301 levodopa (l-dopa) in adults with asthma.
What is the current status of trial NCT02633007?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2015-12. Estimated completion is 2016-05.
What conditions does trial NCT02633007 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT02633007?
The interventions under investigation include: Placebo (OTHER), Carbidopa (DRUG), CVT-301 (levodopa inhalation powder) (DRUG).
Who is sponsoring clinical trial NCT02633007?
This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02633007 being conducted?
This trial has 3 study locations across Florida, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
RECRUITING · Phase 1
-
A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma
RECRUITING · Phase 1
-
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
RECRUITING · Phase 1
-
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.